Diagnostic potential of automated diffusion imaging for the differential diagnosis of multiple system atrophy and Parkinson’s disease
Objective: To evaluate the diagnostic potential of an automated diffusion imaging (DWI) analyses pipeline in separating patients with multiple system atrophy (MSA) and Parkinson’s disease…Comparison of PDE10A and DAT expression as markers of disease burden in early Parkinson’s disease
Objective: We aimed to compare loss of PDE10A and DAT expression in patients with Parkinson’s disease. Background: Recent work has shown loss of PDE10A expression…Regional subcortical volumes predict gait decline in early Parkinson’s disease
Objective: To predict changes in discrete gait characteristics in early Parkinson’s disease (PD) compared to healthy ageing, using subcortical brain volumes quantified in early disease.…Blue light therapy glasses in Parkinson’s disease: patients’ experience and effectiveness
Objective: We aimed to assess how patients experience the use of blue light glasses, a novel way of delivering light therapy, aiming to optimise compliance…Unilateral leg tremor on sitting crossed-legged position as the initial manifestation of Parkinson’s disease
Objective: Our aim is to report an unusual case of initial manifestation of Parkinson's disease, which showed unilateral leg tremor on sitting crossed-legged position on…Prolonged-release Melatonin for Sleep Disorders in Parkinson’s Disease: A Randomized trial
Objective: To evaluate the efficacy of PRM in sleep disorders of patients with PD was investigated. Background: Sleep disorders are highly prevalent in patients with…Efficacy, Safety and Tolerability of Tavapadon in Subjects With Early Stage Parkinson’s Disease
Objective: To evaluate the efficacy and safety of tavapadon (formerly known as PF-06649751) in subjects with early stage Parkinson’s disease. Background: Tavapadon is a potent,…Fatal evolution of cutaneous necrosis in a patient treated with subcutaneous apomorphine infusions
Objective: Report a case of extensive cutaneous necrosis due to apomorphine treatment with fatal outcome. Background: Subcutaneous (SC) apomorphine is used as a treatment of…A Phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Final study results
Objective: The efficacy of isradipine to slow progression of disability in de novo PD participants. Background: There remains no proven therapy to slow progression of…Effect of pill box organizers with alarm on improvement of adherence to pharmacotherapy in patients with Parkinson’s disease: a pilot study
Objective: To find out whether pill box organizers with alarm would improve the rate of adherence in non-adherent patients with Parkinson’s disease (PD) taking three…
- « Previous Page
- 1
- …
- 217
- 218
- 219
- 220
- 221
- …
- 425
- Next Page »